BioGX EU will support customers in Europe, the Middle East and Africa (EMEA) through regional technical sales and field application resources.
The developer and manufacturer of molecular diagnostics CE-IVD tests said the goal was to place sales, supply and support resources closer to European customers.
It applies its platform-agnostic reagent technology across real-time PCR and Next Generation Sequencing platforms.
The Sample-Ready technology is applied within the clinical, food safety, pharma and water quality analysis industries.
Sample-Ready tubes snap into test-specific position on the BD MAX DNA extraction cartridges supplied by Becton, Dickinson and Company.
Shazi Iqbal, CEO of BioGX, said it will offer its full range of products and services to customers in the EMEA region.
"BioGX EU operations will enhance the customer experience and lower costs by eliminating the complexity and expense associated with an international supply chain.”
The Sample-Ready lyophilized qPCR technology was recently selected by the NASA WetLab-2 program to conduct genetic analysis on the International Space Station (ISS).
BioGX launched four CE-IVD infectious disease tests at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) last week.
BioGX Mycoplasma – Ureaplasma, BioGX Pneumocystis jirovecii, BioGX Mycobacterium tuberculosis Complex and BioGX Bordetella Speciation plus Toxin tests are sold by the EU subsidiary and are not available in the US.